Quidel Submits First Test for FDA Approval, CE Marking as MDx Strategy Takes Shape
August 04, 2011
Quidel Submits First Test for FDA Approval, CE Marking as MDx Strategy Takes Shape
Quidel recently submitted a 510(k) package to the US Food and Drug Administration for its first molecular diagnostic assay, a real-time PCR-based test for influenza A and B for use on Life Technologies' 7500 Fast Dx platform.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.